Deutsche Bank
BCLI

Deutsche Bank’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Deutsche Bank’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-140
Closed -$7K – 4247
2021
Q3 		$7K Hold
140
– – ﹤0.01% 4308
2021
Q2 		$8K Sell
140
-1,239
-90% -$66.2K ﹤0.01% 4471
2021
Q1 		$79K Sell
1,379
-38
-3% -$2.87K ﹤0.01% 4096
2020
Q4 		$96K Buy
1,417
+371
+35% +$50.5K ﹤0.01% 3861
2020
Q3 		$265K Buy
1,046
+137
+15% +$28.1K ﹤0.01% 3052
2020
Q2 		$153K Buy
+909
New +$98K ﹤0.01% 3251
2020
Q1 		– Sell
-235
Closed -$15K – 4353
2019
Q4 		$15K Buy
+235
New +$13.6K ﹤0.01% 4377
2018
Q2 		– Sell
-1,994
Closed -$94K – 5406
2018
Q1 		$94K Sell
1,994
-4,579
-70% -$231K ﹤0.01% 4527
2017
Q4 		$386K Buy
6,573
+5,045
+330% +$302K ﹤0.01% 3735
2017
Q3 		$94K Buy
+1,528
New +$98.9K ﹤0.01% 4186

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank's BCLI Position: Q4 2021 in Review

Deutsche Bank sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 140 shares — an estimated $7K sold.

Deutsche Bank first reported a position in BCLI in Q3 2017 and held it in 10 quarters. The position peaked at $386K in Q4 2017. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • Deutsche Bank reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • Deutsche Bank sold 140 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $7K.
  • Deutsche Bank first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 10 quarters.
  • Deutsche Bank's BRAINSTORM CELL THERAPUTC position peaked at $386K in Q4 2017.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on Deutsche Bank's 13F filing for Q4 2021, filed 11 Feb 2022.